Literature DB >> 30617263

No increased risk of VTE with tofacitinib.

Joanna Collison1.   

Abstract

Entities:  

Year:  2019        PMID： 30617263     DOI： 10.1038/s41584-019-0162-5

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.

Authors:  Rishi J Desai; Ajinkya Pawar; Michael E Weinblatt; Seoyoung C Kim
Journal:  Arthritis Rheumatol       Date:  2019-04-29       Impact factor: 10.995
  1 in total
  2 in total

Review 1.  Pathophysiologic mechanisms of cerebral endotheliopathy and stroke due to Sars-CoV-2.

Authors:  Visesha Kakarla; Naoki Kaneko; May Nour; Kasra Khatibi; Fanny Elahi; David S Liebeskind; Jason D Hinman
Journal:  J Cereb Blood Flow Metab       Date:  2021-02-02       Impact factor: 6.960

2.  Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives.

Authors:  Karen Ly; Kristen M Beck; Mary P Smith; Ana-Maria Orbai; Wilson Liao
Journal:  Psoriasis (Auckl)       Date:  2019-08-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.